Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes
Antibody-drug conjugates (ADCs) are novel, highly potent drugs composed of a small molecule of an anticancer drug (payload) attached to humanized antibody recognizing an epitope on the surface of cancer cells. ADCs are rapidly expanding in the oncology field. By 2022, >180 ADC-based clinical tri...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2023-03-01
|
| Series: | Biomolecules & Biomedicine |
| Subjects: | |
| Online Access: | https://www.bjbms.org/ojs/index.php/bjbms/article/view/8874 |
| _version_ | 1827317497025527808 |
|---|---|
| author | Semir Vranic |
| author_facet | Semir Vranic |
| author_sort | Semir Vranic |
| collection | DOAJ |
| description |
Antibody-drug conjugates (ADCs) are novel, highly potent drugs composed of a small molecule of an anticancer drug (payload)
attached to humanized antibody recognizing an epitope on the surface of cancer cells. ADCs are rapidly expanding in the oncology field. By 2022, >180 ADC-based clinical trials have been conducted [1]. Most of these clinical trials are in phases I or II [1]. Several ADCs have been approved and used for the treatment of various malignancies (e.g., brentuximab vedotin (BV) for the treatment of CD30+ lymphomas, trastuzumab emtansine (T-DM1) for advanced/metastatic/or early-stage high-risk HER2-positive breast cancer with residual disease after neoadjuvant treatment) [2].
Read more in the PDF.
|
| first_indexed | 2024-04-24T23:39:50Z |
| format | Article |
| id | doaj.art-2b8fc17512564c50af9d7323f2071731 |
| institution | Directory Open Access Journal |
| issn | 2831-0896 2831-090X |
| language | English |
| last_indexed | 2024-04-24T23:39:50Z |
| publishDate | 2023-03-01 |
| publisher | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
| record_format | Article |
| series | Biomolecules & Biomedicine |
| spelling | doaj.art-2b8fc17512564c50af9d7323f20717312024-03-15T13:22:29ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBiomolecules & Biomedicine2831-08962831-090X2023-03-0123210.17305/bb.2022.8874Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypesSemir Vranic0College of Medicine, QU Health, Qatar University, Doha, Qatar Antibody-drug conjugates (ADCs) are novel, highly potent drugs composed of a small molecule of an anticancer drug (payload) attached to humanized antibody recognizing an epitope on the surface of cancer cells. ADCs are rapidly expanding in the oncology field. By 2022, >180 ADC-based clinical trials have been conducted [1]. Most of these clinical trials are in phases I or II [1]. Several ADCs have been approved and used for the treatment of various malignancies (e.g., brentuximab vedotin (BV) for the treatment of CD30+ lymphomas, trastuzumab emtansine (T-DM1) for advanced/metastatic/or early-stage high-risk HER2-positive breast cancer with residual disease after neoadjuvant treatment) [2]. Read more in the PDF. https://www.bjbms.org/ojs/index.php/bjbms/article/view/8874Editorialsacituzumab govitecanbreast cancer subtypes |
| spellingShingle | Semir Vranic Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes Biomolecules & Biomedicine Editorial sacituzumab govitecan breast cancer subtypes |
| title | Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes |
| title_full | Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes |
| title_fullStr | Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes |
| title_full_unstemmed | Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes |
| title_short | Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes |
| title_sort | sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes |
| topic | Editorial sacituzumab govitecan breast cancer subtypes |
| url | https://www.bjbms.org/ojs/index.php/bjbms/article/view/8874 |
| work_keys_str_mv | AT semirvranic sacituzumabgovitecanexpandsitstherapeuticspectrumamongbreastcancersubtypes |